Polymorphic forms of st-246 and methods of preparation
AssigneeSiga Technologies, Inc.
InventorsShanthakumar R. TYAVANAGIMATT, Melialani A.C.L.S. ANDERSON, William C. WEIMERS, Dylan NELSON, Tove' C. BOLKEN, Dennis E. HRUBY, Michael H. O'NEILL, Gary SWEETAPPLE, Kelley A. McCLOUGHAN
Life of this patent
Estimating the term…
Abstract
Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Claims28
-10. (canceled)
A polymorph Form II of ST-246 which shows a X-ray powder diffraction pattern having characteristic peaks at a reflection angle 20 according to FIG. 2.
A method of treating eczema vaccinatum comprising administering to a patient in need thereof a therapeutically effective amount of the polymorph of claim 21.
-63. (canceled)
A method of producing crystal polymorphic Form II of ST-246, comprising the steps of:
- a) dissolving ST-246 in at least one solvent to make a solution;
- b) cooling said solution to a temperature that causes the preferential crystallization of said ST-246 polymorphic Form II;
- and
- c) optionally drying the formed crystals of ST-246,
- wherein said solvent is selected from the group consisting of ethyl acetate, chloroform and 1-propanol, isopropyl alcohol (IPA), ethanol, acetone, acetonitrile (ACN), toluene, isopropyl acetate and dimethylformamide (DMF).
A method of producing crystal polymorphic Form II of ST-246, comprising the steps of:
- a) dissolving ST-246 in ethanol and water to make a solution;
- b) cooling said solution to a temperature that causes the preferential crystallization of said ST-246 polymorphic Form II;
- and
- c) optionally drying the formed crystals of ST-246.
-94. (canceled)
-114. (canceled)
A unit dosage form for oral administration comprising:
- (a) about 200 mg of ST-246, wherein ST-246 is polymorph Form II;
- (b) about 33.15 mg of lactose monohydrate;
- (c) about 42.90 mg of croscarmellose sodium;
- (d) about 1.95 mg of colloidal silicon dioxide;
- (e) about 13.65 mg of hydroxypropoyl methylcellulose;
- (f) about 7.8 mg of sodium lauryl sulfate;
- (g) about 1.95 mg of magnesium stearate;
- and
- (h) a quantity of microcrystalline cellulose up to about 88.60 mg such that the total weight of the dosage form is about 390 mg.
(canceled)
Dependencies are inferred from the claim text.